SCHEMBL811848

SCHEMBL811848

CC1CCc2ccccc2N1C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ESR1 P03372 1/20 0.48
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MTNR1A P48039 3/20 0.47
CHRM2 P08172 2/20 0.47
CHRM4 P08173 2/20 0.47
CHRM1 P11229 2/20 0.47
TSHR P16473 1/20 0.47
CHRM3 P20309 1/20 0.46
PDK1 Q15118 5/20 0.44
PDK2 Q15119 5/20 0.44
PDK3 Q15120 5/20 0.44
PDK4 Q16654 5/20 0.44
SRD5A1 P18405 2/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29659945 1.00 POLB (0.51) POLBL3MBTL1ESR1GAASMN1; SMN2
SCHEMBL9230128 1.00 POLB (0.51) POLBL3MBTL1ESR1GAASMN1; SMN2
SCHEMBL15222054 1.00 POLB (0.51) POLBL3MBTL1ESR1GAASMN1; SMN2
Citric Acid SCHEMBL10413701 0.80 CHRM2 (0.45) POLBL3MBTL1ESR1GAASMN1; SMN2
SCHEMBL7733992 0.79 NOTUM (0.55) SMN1; SMN2CHRM2CHRM4CHRM1CHRM3
SCHEMBL811795 0.79 NOTUM (0.55) SMN1; SMN2CHRM2CHRM4CHRM1CHRM3
SCHEMBL31672940 0.79 NOTUM (0.55) SMN1; SMN2CHRM2CHRM4CHRM1CHRM3
SCHEMBL6890897 0.79 NOTUM (0.55) SMN1; SMN2CHRM2CHRM4CHRM1CHRM3
SCHEMBL6114443 0.78 POLB (0.47) POLBL3MBTL1ESR1GAASMN1; SMN2
SCHEMBL14705669 0.78 POLB (0.47) POLBL3MBTL1ESR1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110117282-A A kind of zinc ion fluorescent compound and the preparation method and application thereof 五邑大学 2019-08-13 CN claimed
WO-2024116207-A1 ADAR1 INHIBITORS AND METHODS OF USING THE SAME AVAMMUNE THERAPEUTICS INC. (IN) 2024-06-06 WO disclosed
CN-116239529-B Preparation method of N-methyltetrahydroquinoline alkaloid with participation of carbon dioxide 山西大学 2024-05-24 CN disclosed
EP-3681885-B1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-02-28 EP disclosed
WO-2023244815-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
CN-116768733-A Aryl cyclic ammonium salt arylation and silicon-based method 中国科学技术大学 2023-09-19 CN disclosed
CN-116239529-A Preparation method of N-methyltetrahydroquinoline alkaloid with participation of carbon dioxide 山西大学 2023-06-09 CN disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed
WO-2020228640-A1 ZINC ION FLUORESCENT PROBE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 五邑大学 2020-11-19 WO disclosed
CN-110117282-A A kind of zinc ion fluorescent compound and the preparation method and application thereof 五邑大学 2019-08-13 CN disclosed
US-5962731-A MODIFY LIPID METABOLISM; SKIN DISORDERS,; AUTOIMMUNE DISEASES; FATTY ACID METABOLISM; ANTITUMOR AGENTS LIGAND PHARMACEUTICALS INCORPORATED (US) 1999-10-05 US disclosed
EP-0678087-B1 COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS LIGAND PHARM INC (US) 1999-03-17 EP disclosed
US-5780676-A BICYCLIC BENZYL, PYRIDINYL, THIOPHENE, FURANYL, PYRROLE, AND POLYENOIC ACID DERIVATIVES LIGAND PHARMACEUTICALS INCORPORATED (US) 1998-07-14 US disclosed
CN-1150799-A Benzoheterocyclic derivatives OTSUKA PHARMA CO LTD (JP) 1997-05-28 CN disclosed
EP-0678087-A1 COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS LIGAND PHARMACEUTICALS, INC. (US) 1995-10-25 EP disclosed
EP-0637297-A4 COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS. LIGAND PHARM INC (US) 1995-09-20 EP disclosed
WO-1995004036-A1 COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS LIGAND PHARMACEUTICALS INC. (US) 1995-02-09 WO disclosed
EP-0637297-A1 COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS LIGAND PHARMACEUTICALS, INC. (US) 1995-02-08 EP disclosed
WO-1994015901-A1 COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS LIGAND PHARMACEUTICALS INC. (US) 1994-07-21 WO disclosed
WO-1993021146-A1 COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS LIGAND PHARMACEUTICALS INCORPORATED (US) 1993-10-28 WO disclosed